In the 1960s, our predecessors won a historical battle against acute rejection and ensured that transplantation became a common life-saving treatment. In parallel with this success, or perhaps because of it, we lost the battle for long-lived transplants, being overwhelmed with chronic immune insults and the toxicities of immunosuppression. It is likely that current powerful treatments block acute rejection, but at the same time condemn the few circulating donor cells that would have been able to elicit immunoregulatory host responses towards the allograft. Under these conditions, spontaneously tolerant kidney recipients -i.e. patients who maintain allograft function in the absence of immunosuppression -are merely accidents; they are scarce, mysterious and precious. Several teams pursue the goal of finding a biomarker that would guide us towards the 'just right' level of immunosuppression that avoids rejection while leaving some space for donor immune cells. Some cellular assays are attractive because they are antigen-specific, and provide a comprehensive view of immune responses toward the graft. These seem to closely follow patient regulatory capacities. However, these tests are cumbersome, and require abundant cellular material from both donor and recipient. The latest newcomers, nonantigen-specific recipient blood transcriptomic biomarkers, offer the promise that a practicable and simple signature may be found that overcomes the complexity of a system in which an infinite number of individual cell combinations can lead possibly to graft acceptance. Biomarker studies are as much an objective -identifying tolerant patients, enabling tolerance trials -as a means to deciphering the underlying mechanisms of one of the most important current issues in transplantation.
Introduction
As described initially in 1953 by Billingham, Brent and Medawar in a murine model, transplantation tolerance is an acquired state in which immunocompetent recipients have developed donor-specific unresponsiveness [1] . Sixty years later, tolerance appears, more than ever, to be a highly desirable goal in transplantation. The use and development of immunosuppressive drugs have provided a means of controlling acute transplant rejection and have established transplantation as a part of daily medical practice. However, successes in early transplant management have not been accompanied by significant improvements in longterm graft outcomes [2] . Also, non-specific immunosuppression burdens patients with serious side effects such as infections, malignancies, nephrotoxicity and metabolic complications [3, 4] . In kidney transplantation alone, the achievement of lifelong tolerance is expected, intuitively and on the basis of compelling observations, to improve long-term patient and graft outcomes dramatically [5] [6] [7] [8] [9] .
Several protocols have succeeded in inducing tolerance in human leucocyte antigen (HLA)-mismatched human kidney recipients through the achievement, at least transiently, of mixed chimerism [10] [11] [12] . Mixed chimerism refers to a 'hybrid immune system whereby donor pluripotent haematopoietic stem cells engraft and coexist with recipient stem cells giving rise to hematopoietic lineages in the recipient [13] . Eventually, if the engraftment is successful, recipient immune cells develop a selective and durable acceptance to organ and tissue transplants from the same donor [14] . Chimerism can be obtained via various regimens combining non-myeloablative lympho-depleting or immunomodulating interventions in the recipient with a bone-marrow infusion derived from the kidney donor.
Although revolutionary, these procedures remain hampered by the need for highly specialized management, lifethreatening conditioning regimens, a non-competitive success rate and, finally, a failure to prevent slow alloimmune responses [6, 7, 15] . As a result, they have not entered routine clinical practice to date. As detailed by Lombardi et al. in the same issue of CEI, growing efforts are being undertaken by different groups to develop cellular therapies that may contribute to the achievement of more sustainable allograft tolerance [16] .
Conversely, a limited number of kidney recipients who discontinued all immunosuppressive drugs have been able to maintain good allograft function for prolonged periods, in the absence of overt immunodeficiency (see Table 1 ). These patients were qualified as 'clinically operationally or spontaneously tolerant'. They have been studied extensively with three goals in mind: identify specific biomarkers that predict safe immunosuppression minimization in some patients; promote clinical trials aimed at testing strategies of tolerance induction; and discover innovative pharmacological targets for treating rejection or generating tolerance.
The present review aims to summarize current knowledge on operationally tolerant kidney recipients.
Defining an enigma: the need for operational criteria
In animal studies, the claim that an individual has become tolerant has to meet very stringent criteria [46] . [19] 1976 1 36 months Seigler (reply to Uehling) [19] 1976 1 > 4 years Zoller [20] 1980 14 1-8 years Strober [21, 22] 1989 2 69 months and 12 years Burlingham [23, 24] 1995 1 7 years Fischer [25] 1996 1 9 years Christensen [26] 1998 1 > 3 years Van Buskirk [27] 2000 2 § > 5 and > 27 years Cai [28] 2004 1 § 32 years Starzl [5] 2004 7 3-38 years University of Nantes, France [29, 30] 2006 27 ‡ 2-20 years (one missing data) Xu [31] 2007 2 Not available Indices of Tolerance (IOT) [32] 2010 11 2-21 years Immune Tolerance Network (ITN) [33] [34] [35] 2010 39 Divided into 3 groups: (1) n 5 25, mean time: 16 6 10Á4 (2) n 5 7, mean time: 14 6 17Á1 (3) n 5 7, not available Azancot [36] 2011 2 ‡ 14 months and > 6 years Inal [37] 2011 1 8 years University of São Paulo, Brazil [38] [39] [40] 2012 5 1Á5-8 years Becker [41] 2012 4 1-19 years Roedder [42] 2014 69 Not available GAMBIT study [43, 44] 2016 14 # 1 common 1-22Á5 years DESCARTES-Nantes Survey [8] 2016 40 # 1 common 1-25 years (5 missing data) Kesiraju [45] 2016 1 > 3 years Total 41 years of reports 247 -It is likely that some operationally tolerant patients were involved in more than one report. When known, shared cases have been marked by identical symbols ( ‡ , # , § ). We did not mention reports concerning exclusively patients with a history of combined kidney and bone marrow transplantation. Investigators must provide measurable evidence of prolonged allograft survival in the absence of any immunosuppression with normal function, normal histology and the suppression of donor-specific responses using in-vitro assays. Frequently, the demonstration of acceptance by the tolerant recipient of a second donor strain graft, but rejection of a third-party graft is also required. This extensive demonstration is naturally not suitable for patients, for obvious ethical and practical reasons. Histological examination, although theoretically feasible, is rarely performed due to the reluctance of both patients -who are often poorly compliant -and clinicians to biopsy a wellfunctioning kidney. In-vitro assays require donor material that is often not available. In addition, no assay has been validated so far that correlates with the maintenance of tolerance, questioning the value of monitoring. Disappointingly, in clinical practice, the ultimate definition of clinical tolerance will be limited to the demonstration of long-lasting, good allograft function, without overt signs of rejection or immunodeficiency [29, 46] . Depending on the authors, good graft function is defined as either stable or excellent kidney function with a serum creatinine below 150 lmol/l and no gross glomerular proteinuria (< 1 g/day) [29] (for details, see Table 2 ). All authors agreed upon a strict minimal period of 1 year without immunosuppression before evoking tolerance. Importantly, this choice of duration criterion strongly impacts the prevalence of tolerance. Zoller et al. showed that among a selected population of 48 kidney transplant patients, the majority of whom were recipients of a living-related transplant who discontinued their immunosuppression, 16 maintained good graft function at 1 year but only six at 3 years. Notably, none of the cadaveric transplant recipients maintained stable graft function for longer than 2 years without immunosuppressive therapy [20] .
REVIEW SERIES: IMMUNE TOLERANCE IN TRANSPLANTATION
This gap between experimental and clinical definitions of tolerance has a major implication: we cannot assume that all operationally tolerant patients are truly immunologically tolerant. The first reason is technical. While obtaining a kidney biopsy is problematic, as mentioned above, serum creatinine is known to be a poor surrogate of early-stage immune injuries. Consequently, a patient developing subclinical rejection following discontinuation of immunosuppression will meet operational tolerance criteria as long as he maintains a stable creatinine. In addition, several authors have reported that longstanding drugfree graft function can be associated with the presence of donor-specific anti-HLA antibodies (DSA) [8, 30, 33, 41, 48] .
In conclusion, the terminology of 'operational tolerance' is somewhat misleading, because it suggests an equivalence between operational and experimental tolerance which may not be appropriate for all cases [49] . An increasing number of authors talk about 'longstanding absence of nondeleterious/nondestructive immune responses' [48, 50] or 'immunoquiescence' [42] instead. The lack of formally ruled-out subclinical rejection in supposedly operationally tolerant patients may suggest there is no value in studying those patients [51, 52] . We believe that, from a clinical perspective, all patients displaying prolonged allograft survival without immunosuppression deserve our interest, regardless of the mechanism involved.
Clinical presentation

Circumstances of discovery
In current practice, operational tolerance is a rare serendipitous finding, occurring in a limited number of circumstances and patients. Most tolerant individuals are noncompliant patients who weaned themselves off treatment for various reasons (e.g. personal beliefs, excessive side effects, oversight, mental disorder, social issues) (Massart et al., unpublished) . Those who felt well or 'better' continued in that direction. Furthermore, they often hide this behaviour from the medical team; for instance, by taking immunosuppressive drugs that can be monitored in blood only before visits [53] . Drug discontinuation could take months or years with several phases of 'stop-and-start' [29] . A second group of tolerant patients includes those who were advised to suspend immunosuppressive drugs by the medical team when confronted with a life-threatening complication, either oncological (typically a lymphoma) or infectious. Thirdly, some patients who have benefited from an external intervention such as total lymphoid irradiation [21] or combined/successive kidney and bone marrow transplantations (BMT) from the same donor, in the setting of a haematological malignancy, have developed operational tolerance (reviewed in [54] [25] ). While this is an intriguing observation, the low number of cases does not allow us to draw firm conclusions about facilitated kidney allograft acceptance during pregnancy.
Frequency
It has been known from the early days of transplantation that recipient immunosuppression is required to maintain kidney allograft function beyond 48 h [55] . Attempts to reduce immunosuppression from standard treatment levels after the first semester/year of transplantation were also associated with a significant risk of graft loss [56] . Recently, two prospective controlled trials of gradual calcineurin inhibitor weaning in highly selected patients were terminated prematurely because of unacceptably high rates of rejection and alloimmunization [57, 58] . Finally, patient non-compliance [59] has been shown to increase significantly rates of late acute kidney rejection [59] and graft loss [60, 61] .
To our knowledge, fewer than 250 patients, from among several hundred thousand transplantations (see Table 1 for details), have been reported to have discontinued treatment successfully. Operationally tolerant patients, under the current era of immunosuppression, are very rare [5] . We recently performed a Europe-wide survey to identify how frequently these observations were made [8] . A total of 147 centres with a cumulative experience of 218 913 kidney transplantations participated. Overall, we estimated the cumulative incidence of operational tolerance at three per 10 000 kidney recipients (0Á03%). We concluded that this rate was an under-estimate for methodological reasons and because non-compliance is, by nature, surreptitious. However, in the similar context of liver transplantation, clinical tolerance is achieved in 20-40% of selected patients [49, 62] , supporting the view that tolerant kidney recipients are definitely much more rare.
Interestingly, operationally tolerant patients seemed to be, proportionally, significantly more frequent in the early days of transplantation. Starzl and colleagues reported that among the 46 recipients of allografts from living related donors treated in Colorado between 1962 and 1963, nine achieved extra-long graft function for approximately 4 decades. Seven of nine patients displayed an immunosuppression-free period ranging from 3 to 38 years, in spite of HLA mismatches and even ABO incompatibility in one [5] . Starzl and co-workers theorized that immune cell migration and repopulation in the recipient was a critical step in every transplantation, either haematological or solid [63] . This very powerful theory is at the origin of the very first successes in inducing tolerance in humans [64] . By the end of 1963, most teams worldwide started using stronger immunosuppressive treatments, in particular prophylactic steroid bolus, in order to thwart the occurrence of irreversible acute rejection. Starzl and colleagues postulated that these new therapeutic practices may have eliminated migratory donor cells ('passenger leukocytes'), thus blocking rejection but in return also preventing the 'coexistence of donor and recipient cells each to the other' , currently termed 'chimerism' . Our successes in opposing acute rejection seemed to come at the price of a dramatic reduction in long-term survival.
Patient description
Baseline characteristics of operationally tolerant kidney recipients 'do not seem to differ greatly from other kidney recipients in general' [29] . The recent Developing Education Science and Care for Renal Transplantation in European States (DESCARTES)-Nantes survey, which sums up the characteristics of 61 active or past tolerant kidney recipients from across all of Europe, the largest phenotypical description so far, supports that contention. Indeed, most patients were male in their 30s at the time of transplantation and they received an HLA-mismatched cadaveric transplant (average HLA A/B/DR-mismatch number of 2Á8 6 1Á1 in 41; no mismatches in 13; proportion of cadaveric transplants versus living donors was 42 of 61). More than one-third were allosensitized before transplantation. All conventional immunosuppressive drugs seemed to be compatible with the later development of tolerance, including induction with steroids and monoclonal antibodies. In terms of background, autoimmune diseases were sometimes observed but, notably, few diabetic nephropathies (four of 61). Donors were quite young (30Á7 6 13 years) and, together with others, we suggest that the quality of the graft could facilitate the establishment of tolerance [8, 29] . Importantly, a past history of acute rejection was common (eight biopsy-proven in 61 patients), as reported previously [17, 23, 25, 30, 34, 36] . Taken together, data on the preliminary characteristics of tolerant patients support the view that tolerance is an acquired condition rather than a constitutive predisposition, the result of favourable matching or immunosenescence.
The state of tolerance results from an active process specific to the allograft. During their immunosuppression-free period, tolerant patients experienced fewer infections compared to the period before drug weaning and compared to stable, matched controls under immunosuppression [29] . Ballet and colleagues have shown that some tolerant patients, although not all, were able to mount a humoral response following influenza vaccination [65] .
A few histological examinations of tolerant allografts have been published [21, 24, 27, [29] [30] [31] 36, 41] . Biopsies from stable tolerant patients revealed lymphoid infiltrates in peritubular regions of the cortical interstitium, without tubulitis [41] . Such infiltrates are common in wellfunctioning allografts [66] . Compared to stable and rejecting patients, tolerant patients displayed an increased proportion of forkhead box protein 3 (FoxP3)-positive lymphocytes and distinct expression of several proteins involved in the nuclear factor kappa B (NF-jB) pathway [41] . Interestingly, FoxP3 CD4
1 T cells were not distributed uniformly in the interstitium, but were found in cell aggregates. These agglomerates could be part of tertiary lymphoid structures [31] and the cortical interstitium is notable for the presence of resident dendritic cells [67] . . In models of metastable tolerance in Rhesus monkeys, the disappearance of TGF-b cells coincided with the onset of rejection [69] . It is thought that inflammation 1 TGF-b-induced T regs (Tr1/ IL10) could give rise to a more stable tolerance [35] .
Operational tolerance seems to be a metastable condition that could be limited to several years or persist for decades [8, 30] . Biopsies performed in cases of declining function have shown two main patterns, either lesions resembling antibody-mediated rejection with characteristic peritubular capillaritis, lymphomacrophagic infiltrates and glomerulitis, slight immune deposits but, notably, no C4d staining, or nephroangiosclerosis with interstitial fibrosis and tubular atrophy [29, 30] . To our knowledge, a single case of confirmed humoral rejection with positive anti-C4d staining has been described [36] . Circulating anti-HLA antibodies were reported in both histological patterns [30] and do not seem to predict graft outcome reliably [48] .
Biomarkers: somewhere between hope and reality
In contrast to liver recipients, kidney recipients who fail to develop tolerance during an immunosuppression weaning protocol are at risk of irreversible graft rejection and loss of function [49, 70] . Today, the lack of clinically validated biomarkers is a crippling obstacle to bringing tolerance to a larger set of kidney recipients. Immediate objectives for the use of biomarkers would be to detect already tolerant patients and also patients who might potentially develop tolerance in the future, presenting a pivotal signature indicating their aptitude or not for further tapering of immunosuppressive drugs. As operational tolerance is not stable in nature -actually no more in the experimental context [1, 69, 71] than in humans [6, 8] -the ultimate goal would be to identify actionable biological targets in order to programme or refresh selective tolerance as necessary.
Antigen-specific assays for measuring tolerance T cell reactivity. Consistent with the original description of tolerance by Billingham and colleagues [1] , ex-vivo assessments of donor antigen-specific T cell responses were explored early on as a way to detect or predict tolerance. Those assays measured either: (1) proliferation of recipient T cells in a mixed lymphocyte reaction (MLR) [23, 26] , (2) lysis of donor T cells in a cytotoxic T lymphocyte assay (CTL) [23] or (3) production of interleukins with either an enzyme-linked immunosorbent assay (ELISA), enzymelinked immunospot assay [interferon (IFN)-g ELISPOT] [32] or intracellular staining [33] . A systematic description of these assays is beyond the scope of this review and can be found in [72, 73] .
Most of the above tests were used to investigate T cell responses towards antigens presented by donor cells (direct pathway). They provided evidence that operationally tolerant patients were hyporesponsive towards donor antigens while fully responsive to third-party donors [23, 26, 32] and microbial antigens [19] . However, hyporesponsiveness of T cells against donor antigens in CTL or MLR has also been a common finding in stable immunosuppressed long-term kidney recipients [74] [75] [76] . Donor-specific hyporesponsiveness is not synonymous with tolerance. In support of that, Weimar et al. described a patient who was diagnosed with acute rejection weeks after having stopped all his medication, despite favourable CTL results [77] . Nevertheless, several longitudinal studies support the idea that the assessment of direct T cell responses by CTL-derived or IFN-g ELISPOT methods might be a valuable tool in predicting limited uneventful drug tapering, either from steroids [78, 79] , anti-metabolite [77, 80] or calcineurin inhibitors [81, 82] .
So far, the use of such cellular assays has been hindered by the lack of large and consistent studies [83] and low practicability. Indeed, cellular tests require recurrent live donor cell samples [72] . This could, however, be overcome by cell culture followed by cryopreservation [21, 84] . Finally, there has been a concern that this approach was neglecting exploration of the indirect pathway of allorecognition [72, 85] , thought by many to have a critical role in driving long-term transplant immunogenicity.
More recently, authors have favoured assays that are able to explore the indirect pathway over traditional MLR and CTL, and have tried to focus upon the most relevant memory T cells [85] that are only weakly eliminated by traditional depleting agents [86] . Indirect allorecognition testing is feasible on condition that donor antigens be presented as protein lysates together with recipient antigenpresenting cells [72] . In kidney transplantation, this is performed via ELISPOT [87] or trans-vivo delayed-type hypersensitivity (tvDTH) assays [27] . Basically, the tvDTH assay consists of injecting sensitized recipient T cells, collected after transplantation, with donor antigens and recipient antigen-presenting cells into the footpad or the ear of a severe combined immunodeficiency mouse. Responding recipient cells will produce a DTH reaction locally, apparent as a swelling, which can be measured with a calliper.
This assay was the only one to be explored among tolerant kidney recipients. First, Van Burskirk et al., in a study of three tolerant patients, demonstrated a selective absence of tvDTH responsiveness to donor antigens. Importantly, the non-responsiveness was transmissible to control immunogenic recall antigens [either tetanus toxin or Epstein-Barr virus (EBV) lysates] injected with donor antigens into the same footpad, suggesting the presence of an active suppressive mechanism triggered by donor proteins [27] . The same team from the University of Wisconsin showed, in non-human tolerant primates and in humans, that this process relied upon CD4 1 CD25 low adaptive T regs [31, 69] . Also, it was dependent upon cytotoxic T lymphocyteassociated antigen 4 (CTLA-4) and TGF-b or IL-10 [27, 28] .
Once more, defective indirect responses are not the privilege of tolerant patients and can be observed in half of stable kidney recipients [87, 88] with no clear prognostic significance [88] . However, Haynes et al. observed that stable recipients displayed a wider range of tvDTH response intensities compared to the uniform unresponsiveness of tolerant recipients. Actually, there was a progression of tvDTH responses between, in ascending order, tolerant patients, stable patients on steroid monotherapy and on standard therapy and, finally, rejecting patients. They demonstrated that tvDTH responses in rejecting patients required both IL-17 and IFN-g. Conversely, the lack of tvDTH responses in tolerant patients (n 5 11) relied upon TGF-b but not on IL-10 (three patients explored), evoking a T regulatory pattern of the Th3 subtype.
Also, and importantly, aside from tvDTH unresponsiveness, donor-specific regulation, the capacity of donor cells to transfer their hyporesponsiveness to recall antigens injected at the same place, seemed to be notably less frequent in stable immunosuppressed recipients [89] than in tolerant recipients. In a cohort of 71 stable kidney recipients, donor regulation was correlated strongly with the quality of the HLA matching, thus indirectly offering a possible explanation for the better graft survival observed with better matching [90] . In a longitudinal study of 32 stable kidney recipients, donor-specific regulation capacity neatly predicted the outcomes following steroid withdrawal [91] . To date, however, clinical evaluations and possible applications of tvDTH are limited by the cumbersome technique, the requirement of mice and the need for high cell numbers.
B cell sensitization. The detection of DSA, a current practice in clinical transplantation, appears to be less sensitive with current methods than T cell sensitization [88, 89] . The appearance of de-novo DSA has been associated with poorer prognosis in renal transplantation, but recent studies have shown that DSA toxicity depends upon the antibody isotype and capacity to fix complement fractions [92, 93] . The appearance of de-novo DSA in tolerant patients does not seem to preclude, in all cases, the continuation of tolerance [48] . Further studies on DSA subtypes are needed. It is undisputable that the presence of a specific alloimmunization is not, per se, an irreconcilable obstacle to tolerance, as is proven every day in the fetomaternal model of tolerance [94] .
The search for antigen-independent biomarkers
There is an important need to find a practicable biomarker that allows for repeated and non-traumatic monitoring and is affordable, sensitive and highly specific in order to avoid abusive drug minimization in patients. The ideal biomarker would recapitulate, without delay, the situation inside the allograft. Urine seems to be the most pertinent fluid in our context, but its handling often requires tricky and limiting procedures [95, 96] . Blood gene expression studies and cell phenotyping have been the most explored routes and are developed in the following sections.
Two methodological issues have complicated the development of blood signatures in the field of kidney transplantation. The first difficulty in finding a reliable biomarker of tolerance lies in the rarity of patients. This constraint has been overcome through the development of large research consortia in the United States ['Immune Tolerance Network' (ITN)] and in Europe ['Indices of Tolerance' (IOT), 'Reprogramming the Immune System for the Establishment of Tolerance' (RISET), 'Genetic Analysis and Monitoring of Biomarkers of Immunological Tolerance' (GAMBIT Study), 'The ONE Study', 'Bio-DRIM']. These include active initiatives and those that have just begun (for details see [97] ). Beyond their ability to recruit patients, these initiatives have added value in that they have developed standardized operating procedures that promote patient comparisons. Recently, the DESCARTES European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) working group has taken advantage of its unique Europe-wide network devoted to kidney transplantation to support these efforts by collecting biological samples from very rare operationally tolerant patients in order to support further molecular studies ['TOlerance MOlecular and Genome-wide studies with Renal Allograft recipient Material' (TOMOGRAM study), ongoing].
The second challenge in studying potential biomarkers of tolerance is the lack of an adequate control population [95] , illustrated in Fig. 1 . Basically, operationally tolerant patients have been compared to patients without transplant (e.g. healthy volunteers) or to transplanted patients with various degrees of kidney disease and immunosuppression (e.g. stable transplants, under standard or reduced immunosuppression, or rejecting patients, most often chronically rejecting, as it has been postulated that they display a more distant gene expression profile from tolerant patients than patients in acute rejection [47] ).
In addition, as illustrated in Fig. 1 , countless confounding factors may influence transcriptomic signatures including personal features (age, gender, ethnicity or other genetic background features [98, 99] ), environment (transplant, immunological, and infectious history [100] ), medications, sampling procedures [101] or blood cell subset composition [102] . Regarding the limited number of tolerant patients enrolled in studies, all these sources of heterogeneity promote bias and complicate generalization. Finally, in the absence of a clear gold standard for diagnosis of operational tolerance, it is likely that some tolerant patients who are ignorant about their condition contaminate the control groups. Depending on the studies, tolerance biomarkers were detected in zero (at 1 year posttransplant) to one-fourth of the presumed stable controls [42, 47, [103] [104] [105] (illustration in Table 3 ). This overlap makes comparison less powerful.
Phenotypical studies of circulating immune cells
Flow cytometry analysis allows the description of cell subset composition in operationally kidney recipients.
T cell counts seem to be only minimally altered. Operationally tolerant patients display similar [32] [32, 38, 107] , while they are decreased in chronically rejecting patients [38, 107] .
The apparent lack of modification of the global CD4 1 CD25 high FoxP3 T reg population in spontaneously tolerant patients may come as a surprise, as their role in establishing tolerance has been documented widely [109] . We illustrate below how current blood cell immunophenotyping methods have masked the presence of genuine expansions of donor-specific T reg populations in operationally tolerant patients.
First, blood levels of FoxP3 T cells are most probably poor surrogates of the situation inside the graft. Indeed, direct investigations on biopsies from operationally tolerant kidney recipients reveal a proportional increase in FoxP3 expression in allograft infiltrates compared to stable, rejecting patients and healthy controls [41] . In subclinical and acute rejections alike, intragraft and urinary explorations support the view of locally enhanced FoxP3 T cells playing a role in counter-regulation towards deleterious alloimmune responses [110, 111] . However, data are less clear in chronic injuries [111] .
Secondly, it appears that T cell regulatory functions may actually dissociate from FoxP3 mRNA expression [112] and may be appraised more adequately by the demonstration of DNA demethylation at the FoxP3 gene locus [113] . As proof of concept, based on this last method, Braza et al. showed a specific increase in CD4 1 CD45RA -FoxP3 high memory regulatory T cells in the blood of tolerant kidney recipients compared to rejecting or stable patients and healthy controls [114] . In addition, they demonstrated that the memory T regs from tolerant subjects had intact suppressive properties in vitro and, with regard to healthy volunteers, harbour higher surface levels of CD39 and glucocorticoid-induced tumour necrosis factor (TNF)-related receptor (GITR), two molecules with established immunoregulatory functions.
Patent changes in B cell distribution. Several groups have consistently shown increased numbers and percentage of B cells within peripheral blood mononuclear cells (PBMC) in tolerant recipients compared to various groups of immunosuppressed recipients [32, 33, 35, 106, 107, 115] . With very few exceptions [32] , B cell counts were similar to those of healthy controls. Tolerant patients consistently exhibited a Fig. 1 . The multiplicity of factors that influence blood transcriptomic signatures. The four men represent specific patient group signatures (CR, STA, TOL and HV represent patients in chronic rejection, stable patients under immunosuppression, operationally tolerant patients and healthy volunteers, respectively). In the absence of univocal diagnostic criteria for operational tolerance, the STA group is contaminated by unrecognized tolerant patients. The boxes above the figures contain non-exhaustive lists of confounding factors that can alter a group's signature if they arise as uncontrolled stratification factors. The circles below the figures represent the factors that will affect certain patient groups selectively. None of the groups are distinct from tolerant patients solely by lack of tolerance. Overall, the heterogeneity of factors, particularly in the context of small group sizes, promotes bias and complicates generalisation. 
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high CD38 high ) populations in comparison to immunosuppressed patients [32] [33] [34] [35] 116] and, occasionally, to healthy subjects [33] . Consistent with this finding, Chesneau and colleagues reported a decreased frequency of terminally differentiated plasma cells [116] in tolerant recipients compared to stable transplanted patients, suggestive of a truncated differentiation profile. However, discordant observations were made with regard to memory subsets [32, 33, 115, 116] , which are perhaps related to the choice of different surface antibodies (summarized in [50] ).
In line with these observations, several fundamental [117, 118] and mechanistic studies presented here support the view that B cells play a critical role in transplant tolerance [119] . B cells taken from tolerant patients proliferate normally in vitro but display a regulatory phenotype, attested by the expression of inhibitory signals [decreased FcgRIIA/FcgRIIB mRNA ratio, increased B-cell scaffold protein with ankyrin repeats 1 (BANK1) mRNAs, increased surface expression of CD1d and CD5] [115] and an enhanced production of IL-10 upon stimulation compared to stable recipients and/or healthy controls [33, 39, 43, 115, 116, 120] . Regulatory B cells have been shown to inhibit CD4 1 CD25 -effector T cell proliferation and to promote their apoptosis through a contact-and granzyme B-dependent, TGF-b and IL-10-independent mechanism [120] . This latter point is, however, debated, as another report in tolerant patients has advanced that IL-10 has a central role in mediating CD86 down-regulation in B cells and indirectly decreases T cell proliferation [43] . B cells with an inhibitory profile are not found exclusively in tolerant patients, but are more prevalent compared to healthy controls and stable transplants [115, 120] . Their number is IL-21 dose dependent and, in turn, in tolerant patients only, increases the number of IL-21-producing T cells [120] . The skewed B cell distribution results from a unique differentiation profile driven along actively with an increased apoptosis rate [116] . Regulatory B cells (B regs ) have been recognized to play a role in various clinical situations [121] . However, no specific biomarker has been identified so far. Different levels of maturation are compatible with this regulatory phenotype. It is not yet clear whether they play a determinant role in the development of tolerance or are just involved in its maintenance.
Interestingly, B cells that look to be the hallmark of kidney tolerance do not appear to play a major role in liver tolerance [106, 122] . Blood transcriptomic and cellular features of liver tolerance have predominantly designated NK and gd T cell receptor (TCR 1 ) T cells as the major players.
Many cell subsets are involved. In renal transplantation, some groups have also reported changes in other blood cell populations [32, 33, 42] . A significant shift towards higher numbers and ratios of NK cells compared to stable transplants or healthy controls has been reported [32, 42] but, again, inconsistently [107] . A shift toward monocytederived dendritic cells at the expense of T cells has also been reported compared to both stable and tolerant kidney recipients [42] . Currently, numerous cell populations are recognized, through immunophenotyping, gene signature (below) and/ or mechanistic studies, to play a role in driving or maintaining allograft tolerance. The presence of regulatory cells has been attested by their regulatory phenotype and by their suppressive properties in vitro. It is probable that no single cell subset alone is sufficient to trigger graft acceptance but that, altogether, they represent a complex tolerogenic interplay.
Blood transcriptional signatures
Several groups have worked to identify, in the peripheral blood, an enhanced gene expression signature that would characterize operationally tolerant kidney recipients. Here we chose to focus upon whole genome microarray-based transcriptional profiling studies, confirmed by quantitative polymerase chain reaction (qPCR), applied to relatively large cohorts, and either cross-validated or validated on external array platforms. The main findings from these studies are summarized in Table 3 .
The prototype for these studies was that of Brouard et al. [47] , in which they identified 2986 genes of 11 820 spotted on a custom cDNA lymphochip that were expressed differentially between tolerant and rejecting patients. The identified genes suggested a pattern of reduced co-stimulatory signalling, immune quiescence, apoptosis and memory T cells in tolerant patients. Intriguingly, 27% of those genes are assumed to be regulated by TGF-b, though TGF-b protein and RNA levels were similar in both groups. Among differentially expressed genes, they identified a minimal set of 33 genes that were expressed abundantly and that allowed tolerance detection with a specificity of 99%.
Newell et al. [33] , from the ITN, studied a different patient cohort, with distinctly better HLA matches (see Table 2 ). They first compiled a 228-candidate gene list based on an original whole-genome microarray study (Affymetrix array), on previously identified transcripts associated with liver transplant tolerance [123] , and on relevant biological targets. They performed multiplex PCR and settled on a set of 31 transcripts that were expressed differentially between tolerant subjects compared to stable patients but not to healthy volunteers. Most of the genes identified were B cell-specific, with many encoding j/k light chains of immunoglobulins. None of the transcripts associated with liver tolerance were identified in this setting. From those 31 gene transcripts, they delineated a reduced set of three genes [immunoglobulin kappa variable (IGKV)1D-13, IGKV4-1, immunoglobulin lambda-like polypeptide 1 (IGLL-1] with excellent predictive capabilities in an independent subgroup of their cohort.
In subsequent studies, the same team and others demonstrated that IGKV1D-13 transcripts remained persistently elevated, with either IGLL-1 or IGKV4, in tolerant patients over years [34] and increased over time among calcineurin inhibitor-treated patients [34, 103] . Interestingly, IGKV1D-13 was also increased in patients rendered tolerant via induction of transient mixed chimerism [11, 124] and in stable transplants on sirolimus monotherapy [89] , suggesting that the signature may be a common theme to various tolerogenic strategies [34] .
Taking advantage of the original gene expression data set of Newell and colleagues [33] , Sagoo et al. [32] identified 170 genes, very enriched in B cell-related genes, that were expressed differentially among all patient groups in both platforms, i.e. the RISET Agilent 2.0 custom microarray and the one used by Newell et al. As partially expected from the study design, the identified genes were particularly enriched in B cell-related genes, but also in protein tyrosine kinase and other T cell activation-related genes. Through an additive binary regression model, they were able to build receiver operating curves (ROC) with optimal diagnostic capabilities with a restricted set of 10 genes. Of interest, three of those 10 highly discriminating genes [CD79B, T cell leukaemia/lymphoma 1A (TCL1A) and membrane-spanning 4A (MS4A1) (CD20)] are B cell transcripts that were validated further in other transplantation studies. TCL1A and MS4A1 were found eventually to be up-regulated in tolerant recipients in other analyses [34, 113] . In addition, all three genes were reported to be up-regulated in stable rejection-free patients [125, 126] . TCL1A is an oncogene expressed in naive and transitional B cells and directly reflects their abundance [127] . This gene promotes B cell survival and is low or absent from mature B cells. The close relation between TCLA1 expression, immature populations of B cells with recognized suppressive properties and immune activation suggests fine regulation of immune responses all along the spectrum of alloimmunity. Also, the over-expression of an oncogene in renal operational tolerance is intriguing. It raises the possibility that, among tolerant patients who stopped their treatment due to a malignancy, a common latent immunosuppression predisposed them to both cancer while under immunosuppression and, finally, tolerance.
Lozano et al. [106] compared the gene expression patterns from the last two cohorts described above [32, 33] with 12 tolerant patients from Nantes. They found that a limited number of 35 common transcripts (more than 3921 for Newell, 433 for Sagoo et al. and 524 for Lozano) were expressed differentially between tolerant and stable transplanted patients in the three cohorts. Twenty-four transcripts of the 35 were related closely to B cell function.
One conclusion derived from these early works may be that, surprisingly, tolerance signatures eventually indicate shared pathways but have very few genes in common. This heterogeneity has been attributed to small sample sizes, a lack of standardization in sampling methods and data analysis and to wide patient and cellular heterogeneity. Also, it is also possible that several different homeostatic mechanisms allow for tolerance development. The pathways to tolerance could be innumerable, and may take into account personal immune history combined with unique heterologous immunity, memory cell populations and environmental factors [41, 128] . Capturing common trends among a huge number of tolerogenic combinations is complicated further by the rarity of tolerant patients.
Several authors have also reported the poor overlap between liver and kidney transplant tolerance signatures [33, 106] . In their study, Lozano and colleagues observed that only three genes were expressed differentially in both kidney-and liver-tolerant patients when compared to their respective controls (NF-jB2 -involved in NF-jB-inducing kinase (NIK)/NF-jB signalling and germinal centre formation, MPAK1, involved in the Ras pathway, and HIPK2 -that promotes p53/TP53-mediated cellular apoptosis and angiogenesis). In fact, liver-and kidney-tolerant recipients appear to have deeply contrasting gene expression profiles. Using blood cell lineage-specific transcripts, Lozano et al.
showed that B cell-specific transcripts best characterize tolerant kidney transplants but were down-regulated in livertolerant recipients and, conversely, NK-related genes were up-regulated in liver-but not in kidney-tolerant recipients. The discrepancies observed between liver-and kidneytolerance signatures may be due, at least in part, to methodological differences, as was discussed earlier. However, several lines of evidence suggest that liver and kidney tolerance also differ mechanistically. In liver transplantation, an important prospective study by Bohne and colleagues revealed that tolerant recipients displayed altered iron homeostasis, demonstrated by intragraft transcriptomic and histomorphological studies, well before drug minimization [129] . Compared to non-tolerant liver recipients, tolerant patients exhibited enhanced iron deposits in periportal hepatocytes, higher serum ferritin levels and, compared to normal individuals, lower hepcidin/ferritin ratios. Because hepcidin is secreted by hepatocytes, the authors hypothesized that adjustments in iron metabolism may be part of liver-specific tolerogenic mechanisms needed to deal with the continual arrival of antigens via the portal venous blood.
In renal transplantation, repeated findings of B cellrelated biomarkers in tolerance signatures suggest that these cells may play an active role in the development and/ or the maintenance of tolerance. Using IFN-g ELISPOT assays, Shiu et al. [130] demonstrated recently the major contribution of B cells in driving effective versus regulatory indirect T cell responses in the setting of antibody-mediated rejection (n 5 65). Prior to this, Haynes and colleagues had failed to demonstrate that B cell antigen presentation was necessary for generating suppressive indirect T cell responses in a tvDTH-based study on tolerance. However, their conclusion relied upon only two patients, and further experiments were needed [35] . In the liver, multiple, specialized, non-B cells are responsible for antigen presentation with the aim of dampening local inflammatory responses, so the absence of a B cell signal in liver tolerance signatures should not come as a surprise. In conclusion, tolerance signatures are organ-specific and not interchangeable [131] . This is consistent with the daily experience of transplant clinicians. Liver tolerance is relatively common, kidney tolerance is rare and other cases of transplant tolerance (heart, lungs) seem anecdotal.
In an attempt to reconcile discordant renal data, Baron et al. [105] recently performed a meta-analysis of six earlier data sets [32, 33, 47, 106, 132] . Beyond the confirmation of the strong involvement of B cells, they pointed out a role for CD4
1 T cells and an inhibition of CD14 1 monocyterelated functions. From an initial data set encompassing 1846 differentially expressed genes between stable and tolerant kidney recipients in all studies, they were able to isolate 20 genes with good classification (91Á7%) in an external validation cohort. The expression of those 20 genes in tolerant recipients was superimposed on that of healthy subjects.
Early biomarker studies often focused upon identifying a biomarker that would, as a priority, discriminate tolerant recipients from stable transplanted ones from the perspective of drug-weaning trials [32, 33] . Nevertheless, it was a surprise to observe how close tolerant recipients were to healthy subjects. From a physiopathological point of view, this raised the question of whether tolerant patients under immunosuppression had a 'reinitialization of the immune system resulting in recognition of the transplanted graft as self ' [123] . In this scenario, alloreactive cells would have been deleted centrally. However, a blood signature, based on unsorted immune cells, would lack the sensitivity to detect subtle transcript changes restricted to particular cell subsets that would differentiate tolerant from healthy subjects. Also, pressing questions emerged regarding whether most of the previously identified tolerance signatures might just mirror the absence of immunosuppression [35] . It seems obvious now that several of the first-generation tolerance signatures were influenced deeply by immunosuppression [44, 103, 133] . Whether immunosuppressive drugs rightly perturb tolerance signatures in line with their tolerogenic properties or act purely as confounding factors is not clear. However, until we know, it seems prudent to look for tolerance signatures that account for the effects of immunosuppressive regimens to limit sources of error.
In an effort to build a signature that is independent of the immunosuppressive regimen, Rebollo-Mesa et al. applied a multivariate linear model for immunosuppressive drugs on the IOT data set [32] and determined the level of immunosuppression-independent expression for each gene [44] . The genes best discriminating between tolerant and stable patients were connected with NF-jB, CD40, TNF, granulocyte-macrophage colony-stimulating factor (GMCSF) and glucocorticoid networks. The first two can be classified as B cell-related. The team was able to refine this selection into a nine gene-signature with good predictive value in the GAMBIT validation cohort by qPCR measurement (Table 3 ). This signature appeared to be influenced only minimally by immunosuppressive drugs, was stable over time and was almost two times less prevalent in healthy controls (45 versus 85%) . No gene overlapped with the previous IOT signature. In line with this, this new signature predicts completely different individuals as being tolerant in the group of stable patients from the IOT cohort.
The Rebollo-Mesa et al. publication brought into question the previously published evidence. In our opinion, although such a study is progress, one should be careful before rejecting all the conclusions of the previous studies. In particular, the strong B cell signal in transcriptomic signatures was also consistent with experimental data (above), along with repeated occurrences of multi-modal markers that distinguished tolerant from healthy controls. Paradoxically, the systematic gap between kidney and liver transplant signatures of tolerance also conveys that those signatures, even if partly impaired, were due to more than the simple absence of immunosuppressive drugs.
The recent multi-modal biomarker study by Roedder et al. contributed markedly to deciphering the cellular landscape in operational tolerance. They first used a wholegenome Agilent microarray to identify a minimal set of 21 genes that discriminate operationally tolerant (n 5 16), rejecting and healthy controls in a three-class comparison. Seventeen of 21 genes were validated by qPCR in a second external cohort of tolerant (n 5 31) and stable patients. Finally, they circumscribed a minimal set of three genesKruppel-like factor 6 (KLF6), basonuclin 2 (BNC2) and cytochrome P450 family 1 subfamily B member 1 (CYP1B1) -which predicted patient groups in a third independent cohort with 17 additional tolerant patients with 95% accuracy. The primary 21-gene set pointed towards apoptosis networks centred on TNF, IL-6, IL-4, the complement system and, again, B cell activation pathways. Interestingly, CYP1B1 and BNC2 were reported previously in studies on kidney and liver tolerance, respectively [33, 47, 129] .
Restarting from those 21 genes, they identified the cell populations over-expressing each of them in a large public database. They found that seven, seven and six genes of the 21 were expressed characteristically in dendritic cells, B cells and NK cells, respectively. According to a hypergeometric analysis, this could not be expected by chance with this array. They noticed a parallel enrichment in dendritic cells and NK cells, but not in B cells, in the blood of tolerant patients compared to healthy controls. Finally, they showed that their three-gene signature was reproducible with sorted CD11c 1 dendritic cells only. Taken together, Roedder and co-workers brought evidence for a strong role for new players, dendritic cells and NK cells in operational tolerance and its signatures.
Other soluble biomarkers in plasma and or urine Newell et al. reported that several RNAs were increased significantly in the urinary sediment of tolerant patients in comparison to healthy subjects (FoxP3, CD20, CD3 and perforin) or to stable transplants (CD20). While interesting, the predictive value of these tests is unknown [33] .
Sagoo and colleagues described a significantly increased expression of the FoxP3/alpha-1,2 mannosidase ratio in the blood of tolerant recipients compared to different controls. The prognostic value of this finding was not stated, but this could prove useful in combination with other tests. Finally, Danger et al. showed that tolerant patients could be differentiated from stable patients on the basis of the micro-RNA, miR-142-3p, originating mainly from B cells, and independently of immunosuppression therapy [134] .
Biomarker studies are full of promise and have already shed light on possible new roles for different cell types in operational tolerance. So far, however, the lack of consistency among studies has restrained clinician confidence and slowed down clinical applications. The final validation of any signature will only come from a successful prospective trial of drug minimization that would represent real, life-changing progress for the transplantation community and patients.
Mechanisms
Numerous experimental methods allow researchers to induce immune tolerance in laboratory rodents [135] . Apart from chimerism, none of those various reductionist approaches can, alone, induce tolerance in human transplantations [14] . Because the immune system is dedicated to react (or not) towards countless antigens, it is highly redundant and plastic, adapting to changing contexts and over time. It is now generally suspected that tolerance after transplantation in humans reflects this complexity and relies upon a compilation of mechanisms, regulatory dominating over cytotoxic, that act in a timely manner [72, 85] (Fig. 2) .
The concept of 'chimerism' developed by Starzl and coworkers over decades [63] includes, as a corollary, the idea that any solid organ transplantation can be managed as a variation of bone marrow transplantation [64] . Accordingly, they hypothesized that chimerism probably underlies the development of operational tolerance in kidney recipients [5] . In fact, notwithstanding those postulates, later studies have revealed that donor T cell engraftment (i.e. donor T cell-recipient chimera, instead of donor blood cell-recipient chimera) was the critical step for inducing tolerance [13, 14, 136] .
Most of the current strategies devoted to creating tolerance in human kidney recipients (reviewed in [137] ) can be interpreted, broadly, as attempts to neutralize alloreactive T cells and/or, conversely, attempts to increase the pool of regulatory cells [14] . However, the precise mechanisms by which operational tolerance proceeds are yet to be elucidated. Hypotheses have been built in reference to other mechanisms identified in other settings such as neonatal, infectious and self-tolerance, as well as experimental findings. They include 'central' (thymic deletion) and 'peripheral' mechanisms (ignorance, anergy, regulation or suppression, apoptosis or peripheral deletion) [14, 138] .
Ignorance seems to count for little in the setting of operational tolerance [128] . Ignorance refers to all the factors that prevent recipient T cells to be primed by donor antigens in lymph nodes. The use of intensive T cell-depleting agents (rabbit anti-thymocyte globulins: rATG, alemtuzumab) as the ultimate means of preventing antigen-T cell contacts may have unexpected effects. First, these drugs affect predominantly naive and regulatory T cells [86, 139] . Secondly, and consequently, repopulation by homeostatic proliferation will favour memory or memory-like T cells that have previously encountered antigens cross-reactive to the transplant antigens (heterologous immunity) and elicit a specific response towards the allograft [140, 141] . Re-emerging memory CD8
1 T cells have been associated with failure to induce tolerance in liver transplantation following rATG induction [142] . Biomarker studies presented above are supportive evidence for active processes of regulation in operational tolerance. Both B and T regulatory cells, either natural or adaptive, are present in higher proportions in the blood and/or in the allograft of tolerant kidney recipients. They exert their regulatory properties through surface inhibitory molecules (CD39, GITR, CTLA-4 on T cells; CD1D and CD5 on B cells), cytokine production (TGF-b, IL-10, IL-21), and most probably also by inhibiting antigen presentation by dendritic cells via a cell-contact-dependent mechanism [143] . T cell regulatory properties could be transferred adoptively to other reactive T cells [27, 144] , even memory [28] . Suppression is triggered by dominant Take-home messages
Definitions
In kidney transplantation 'operational tolerance' is a very rare clinical condition characterized by the maintenance of stable graft function in the absence of immunosuppressive drugs for at least 1 year Operational tolerance does not imply the total lack of anti-donor reactivity as shown by the occasional presence of anti-donor HLA antibodies, but the absence of clinically detectable deleterious immune responses directed against the graft
Mechanistic studies
In vitro, T cells from operationally tolerant patients are hyporesponsive toward donor antigens yet fully responsive to third-party donors and microbial antigens In transvivo DTH assays, CD4 
Biomarker findings
Both operationally tolerant patients and rejection-free stable kidney recipients show an expansion of naive and transitional B cell populations with their associated transcripts, in comparison to immunosuppressed patients and rejecting patients, respectively Several antigen-specific cellular assays predicted graft outcomes following drug minimization in longitudinal studies Transcriptomic signatures of operationally tolerant patients recently demonstrated the involvement of multiple cell subsets and biological pathways. However, those signatures still lack validation in prospective drug minimization trials There is little overlap between liver and kidney transplant tolerance blood signatures. These differences probably account for organ specialization in antigen management
Clinical presentation
Baseline characteristics of operationally tolerant kidney recipients do not seem to differ greatly from other kidney recipients in general. A previous medical history of rejection is common Operational tolerance is a metastable phenomenon that could be limited to several years or persist for decades allopeptides from the donor (HLA molecules or minor antigens, either membrane-bound or soluble) and executed by regulatory T cell subsets, CD4 1 or CD8 1 [28, 31] . The most recent transcriptomic studies demonstrated a role for other cell subsets, notably NK and dendritic cells, and an inhibition of monocyte functions. As suggested by those numerous regulatory mechanisms, or by the onset of DSA during an otherwise uneventful tolerance period, clonal deletion is unlikely to be the central mechanism of operational tolerance. As a more formal demonstration, the group from the University of Wisconsin demonstrated that they could regrow specific cytotoxic lymphocytes from hyporesponsive mixed lymphocyte cultures derived from tolerant patients. This could be either performed positively by means of repeated cultures and IL-2 stimulation [23] or negatively by the addition of anti-TGF-b1 antibodies to the culture to deplete regulatory cell populations [31] . In Nantes, Brouard and colleagues observed markedly altered TCR CD3 transcript length distributions inside Vb chain families in tolerant and minimally immunosuppressed patients compared to all traditional controls. The phenomenon was marked mainly in CD8
1 T cells, which accumulated Vb transcripts in an oligoclonal pattern. However, the lack of donor specificity in this method did not allow them to draw formal conclusions on the possibility of partial clonal deletion. Methods based on the direct sequencing of TCR Vb CDR3 may contribute to solving the question in the near future [145] . In contrast to tolerance induced by formal bone marrow transplantation, operational tolerance seems to be dominated by regulation.
Conclusion
Intensive and elegant studies have enabled us to capture several important acts of the tolerance play. However, the acquaintances between the players, of their roles and relationships, and the beginning of the script still elude us. Deciphering more finely the dynamics of tolerance signatures is expected to promote customized patient management and allow cessation of immunosuppression in some. In addition, as it probably stems from a fundamental mechanism, better understanding of operational tolerance will be of general interest far beyond the field of transplantation.
